Black Diamond Therapeutics (BDTX) EPS (Basic): 2018-2021
Historic EPS (Basic) for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to -$0.71.
- Black Diamond Therapeutics' EPS (Basic) fell 12.70% to -$0.71 in Q4 2021 from the same period last year, while for Dec 2021 it was -$3.15, marking a year-over-year decrease of 53.66%. This contributed to the annual value of -$3.47 for FY2021, which is 69.27% down from last year.
- As of Q4 2021, Black Diamond Therapeutics' EPS (Basic) stood at -$0.71, which was up 26.80% from -$0.97 recorded in Q3 2021.
- In the past 5 years, Black Diamond Therapeutics' EPS (Basic) registered a high of -$0.41 during Q2 2020, and its lowest value of -$5.99 during Q2 2019.
- For the 3-year period, Black Diamond Therapeutics' EPS (Basic) averaged around -$1.96, with its median value being -$0.84 (2021).
- In the last 5 years, Black Diamond Therapeutics' EPS (Basic) tumbled by 206.62% in 2019 and then spiked by 93.16% in 2020.
- Black Diamond Therapeutics' EPS (Basic) (Quarterly) stood at -$1.51 in 2018, then crashed by 206.62% to -$4.63 in 2019, then skyrocketed by 86.39% to -$0.63 in 2020, then declined by 12.70% to -$0.71 in 2021.
- Its EPS (Basic) was -$0.71 in Q4 2021, compared to -$0.97 in Q3 2021 and -$0.84 in Q2 2021.